-

Tivic Health to Report Third Quarter 2022 Financial Results on Monday, November 14th

SAN FRANCISCO--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that it will report financial results for the third quarter of 2022 via conference call and webcast on Monday, November 14, 2022, at 1:30 PM PT / 4:30 PM ET.

Teleconference Details:
Toll-Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 290242

Webcast Link:
https://www.webcaster4.com/Webcast/Page/2865/46587

Shareholders also may submit questions in advance of the earnings call by sending them to the following email address - ir@tivichealth.com. The deadline for submitting questions in advance of the webcast/conference call is 5:00 PM ET on November 11, 2022. Due to time constraints and the nature of the questions please be advised that not all questions submitted can be answered.

About Tivic Health

Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and related conditions. For more information visit https://tivichealth.com @TivicHealth

Contacts

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

Media Contact:
Tivic Health
Cheryl Delgreco
Cheryl.Delgreco@tivichealth.com
617-723-4004

Industry:

Tivic Health Systems, Inc.

NASDAQ:TIVC
Release Versions
English
$Cashtags
$TIVC
Hashtags
#healthcare

Contacts

Investor Contact:
Hanover International, Inc.
ir@tivichealth.com

Media Contact:
Tivic Health
Cheryl Delgreco
Cheryl.Delgreco@tivichealth.com
617-723-4004

Social Media Profiles
Tivic Health/Facebook
Tivic Health/Instagram
Tivic HealthLinkedIn
More News From Tivic Health Systems, Inc.

Tivic Expands Intellectual Property Portfolio

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office. The first application applies to Tivic’s TLR5 agonist portfolio, which includes Entolimod and Entolasta. The patent titled “Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy” r...

Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. T...

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to...
Back to Newsroom